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Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome characterized by a non-
malignant expansion of the macrophage population in the setting of a heightened cytokine response
with subsequent widespread hemophagocytosis. It can occur as either genetic or acquired forms; the
latter of which frequently occurs in the setting of infection, autoimmune disease, or malignancy. We
present the second known case of HLH associated Chronic Lymphocytic Leukemia (CLL) in the absence
of infectious etiology and review the current literature.
& 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Case report
A previously healthy 47 year-old male was diagnosed with
symptomatic Rai stage 1 CLL after he presented with progres-
sively worsening cervical adenopathy. He was treated with
Fludarabine and mitoxantrone with a complete remission that
lasted almost 12 years. Subsequently he had 2 relapses requiring
treatment with R-CHOP (rituximab, cyclophosphamide, vincris-
tine, adriamycin and prednisone) and bendamustine/rituximab.
On both occasions transformation was ruled out and the patient
achieved only a partial remission that lasted approximately 30
months each time.
He was doing fairly well until the age of 63 years when he
presented with progressive B symptoms and was diagnosed with
progressive CLL. In view of the previously prolonged complete
remission enjoyed after purine analogue therapy he was started
on pentostatin, cyclophosphamide and rituximab. After two
cycles not only were his symptoms persistent but radiographic
imaging showed progressive disease in addition to a new onset
pancytopenia.
During a routine clinical evaluation he reported fevers and was
subsequently admitted with neutropenic fever and hypoxialogy, Wilmot Cancer Center,
2, USA.
(D. Kilari).
-NC-ND license.presumed to be secondary to Pneumocystis carinii pneumonia.
His blood work on admission was signiﬁcant for a white blood cell
count of 1.2109/L, absolute neutrophil count of 0.6109/L,
hemoglobin of 8.2 g/dL, and a platelet count of 371012/L. He
was empirically treated with broad-spectrum antibiotic, antiviral
and antifungal therapy. Extensive workup for an infectious cause
of fevers which included adenovirus, parvovirus B19, human
herpes virus -6, HIV, histoplasma, Cryptococci, aspergillus,
respiratory syncytial virus, inﬂuenza and legionella was all non-
revealing. His hypoxia improved after several days; however he
continued to remain febrile and pancytopenic despite multiple
transfusions.
Given his unexplained cytopenias 30 days after completion of
chemotherapy even with subcutaneous granulocyte colony sti-
mulating factor and worsening clinical picture, a bone marrow
biopsy was performed suspecting progressive marrow involve-
ment with CLL versus transformation versus delayed recovery
from chemotherapy. The biopsy however, did not show changes
compared to previous biopsy in terms of percent CLL involvement
(Fig. 1). Additional studies on the marrow noted a prominent
population of CD68þ macrophages (Fig. 2) with active hemopha-
gocytosis (Fig. 3). This ﬁnding, in combination with cytopenias led
to further studies which included elevated serum ferritin
(13,000 ng/ml), triglycerides (319 mg/dl), and hypoﬁbrinogen-
emia (145 mg/dl) all pointing to the diagnosis of HLH.
As per the HLH-2004 guidelines (which reports the use of
dexamethasone, etoposide and cyclosporine for 8 weeks, with
Fig. 1. Bone marrow biopsy: hematoxylin and eosin stain (400 ): large lymphoid
cluster replacing marrow with scattered mononuclear cells with abundant
cytoplasm.
Fig. 2. Bone marrow biopsy: immunoperoxidase (400 ): numerous histiocytes
stained with CD68 antibody.
Fig. 3. Bone marrow biopsy: hematoxylin and eosin stain (1000 ): histiocyte
with numerous erythrocytes.
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patient was initially treated with cyclosporine and dexametha-
sone for several days with poor clinical and hematologic
response.[1] The literature was reviewed again and it was felt
that the patient’s HLH could be a secondary phenomenon related
to his underlying CLL and the decision was made to pursue
aggressive treatment of CLL. He received one cycle of R- CHOPwith continued deterioration of his clinical status over the next
3 weeks leading to acute renal failure and respiratory failure,
requiring intubation. Given his poor prognosis he was transi-
tioned to comfort care and passed away shortly thereafter.2. Discussion
HLH in both, genetic and acquired forms can occur in the
setting of infection, autoimmune disorders and occasionally
hematologic malignancies. HLH is suspected to be secondary to
defective NK cell removal of antigen stimulation (through per-
forin dependent cytotoxicity) which in turn causes persistent T
cell activation, macrophage proliferation and hemophagocytosis.
The organ dysfunction is attributed to high levels of cytokines, in
particular soluble interleukin 2 (SIL2) which has been shown to
correlate with prognosis.
HLH generally affects children; however cases of older adults
with this disease have also been reported. Infectious agents
typically involved include Epstein Barr Virus (EBV), cytomegalo-
virus, parvovirus B19 and HIV. Bacteria, parasitic, and fungal
pathogens have also been implicated.[2] Extensive evaluation
for underlying infection was unrevealing in our patient. In
previous reports lack of infection was linked to adverse outcomes.
Malignancy associated HLH represents a heterogeneous group
of mostly hematologic malignancies with the hemophagocytic
syndrome appearing either before or during treatment. The
clinical course in most of these patients is complicated by
infections which can shadow the diagnosis of HLH. T-cell lym-
phoma associated HLH both with and without EBV positivity has
been well documented.[3,4] In comparison, only a few cases of B-
cell lymphoma associated HLH have been reported and are
predominantly of the large B cell histologic subtype.[5] HLH in
association with acute myeloid leukemia is rare and little is
known of outcomes.[6]
The International Histiocyte society mandates ﬁve of the
following eight criteria to make a diagnosis of HLH: fevers,
cytopenias of at least two cell lines, evidence of hemophagocy-
tosis, hypertriglyceridemia and/or hypoﬁbrinogenemia, hyperfer-
retinemia, elevated SIL2, decreased NK cell activity and
splenomegaly. Our patient had six of the eight criteria, and SIL2
levels were not checked.
CLL associated HLH was ﬁrst documented in the form of a case
series report which included six patients treated for CLL who
subsequently developed the phagocytic syndrome months to
years later.[7] As these cases occurred prior to publication of
the 1991 HLH diagnostic guidelines, the authors postulated that
the syndrome was likely reactive to an occult opportunistic viral
infection and only subsequently suspected HLH. Subsequent case
reports describe CLL associated HLH only in the setting of
infection.[8,9]
The present report describes ‘‘HLH associated CLL’’ in the
absence of an ongoing infectious process. Such an occurrence
has only been reported once by Meki et al. [10] In both situations
the patients were initially treated per HLH-2004 guidelines.3. Conclusion
HLH continues to present diagnostic and therapeutic chal-
lenges. To our knowledge this is the second report where HLH
was suspected to be a secondary to CLL and hence given treat-
ment for underlying CLL. There are no randomized trials to base
treatment decisions on and the goal of treatment is to suppress
inappropriate and uncontrolled inﬂammatory response. Physi-
cians should have a high index of suspicion for HLH in any patient
D. Kilari et al. / Leukemia Research Reports 2 (2013) 4–66who presents with unexplained febrile illness, cytopenias, hepa-
titis, and encephalitis or multi organ failure. Once the diagnosis is
made treatment should be initiated immediately. Further studies
are needed to improve outcomes.
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